Skip to main content

 

Increased SLE Flares with Hydroxychloroquine Reduction

Concerns about the long-term safety of hydroxychloroquine (HCQ) often results in dose reduction or drug discontinuation; yet a current study shows that, for those in remission, HCQ taper/discontinuation resulted in a significantly higher rate of SLE flares.

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.

Low COVID-19 Vaccine Risks in Rheumatic Patients

Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine registry shows that patients with with inflammatory or noninflammatory rheumatic and musculoskeletal disease have similar adverse event rates as the general public.

Hand OA and Heroes in Rheumatology (2.11.2022)

Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com. Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology.

Vitamin D and the Risk of Autoimmune Diseases

The results of the VITAL study (presented at ACR 2021) are now published by BMJ, showing that vitamin D and omega 3 fatty acids reduce the overall risk of autoimmune disease (AID) in a population based intervention trial.

An Ounce of Prevention (2.4.2022)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout. 

MMWR: Booster Vaccine Efficacy in Immunosuppressed Patients

CDC/MMWR

For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.

The Overpricing of Drugs (1.14.2022)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

Hold Myophenolate or Not with COVID-19 Vaccination?

While the American College of Rheumatology (ACR) recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases (RMD) patients receiving COVID-19 vaccines, there is limited data on such an approach.

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.

Best of 2021: Israel provides COVID vaccine answers for rheumatic disease patients

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br

Best of 2021: Potential Birth Defects with Hydroxychloroquine

Hydroxychloroquine (HCQ) is one of the safest meds used in rheumatology, but there is new claims data suggesting a small increase in the risk of malformations associated with first-trimester HCQ use.

Social

#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results

Dr. John Cush @RheumNow ( View Tweet )

2 years 2 months ago
Why Patients Don't Take Medicines This report examines the characteristics of adults aged 18–64 who took prescription medication in the past 12 months and did not take medication as prescribed due to cost. https://t.co/zuPgMjKYbh https://t.co/62cG9LDYWi
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd
Dr. John Cush @RheumNow ( View Tweet )
2 years 3 months ago
With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW
Bella Mehta @bella_mehta ( View Tweet )
2 years 3 months ago
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush @RheumNow ( View Tweet )
2 years 3 months ago
We know HCQ adherence is poor in both RA and SLE >50% in this BC 🇨🇦 cohort All despite being such an important medicine What’s super interesting are the trajectories of adherence - and we’d like to understand more about what motivates each group OP0222 #EULAR2023 @RheumNow https://t.co/rbx1l9T36C
David Liew @drdavidliew ( View Tweet )
2 years 3 months ago
Antimalarial adherence in RA and SLE showed 4 patterns of adherence over time, with 53% drop off in 1 year, with higher adherence with age, SLE and socioeconomic class, Hoque MR, Abst#0222 #EULAR2023 @RheumNow https://t.co/Bld5kWVQxE
Dr. Antoni Chan @synovialjoints ( View Tweet )
2 years 3 months ago
#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results @RheumNow https://t.co/UoZ2xS3IzC
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years 3 months ago
#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed: - 1 in 10 people had AID in the last 20yrs - socioeconomic, seasonal & regional disparities cd influence pathogenesis - CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years 3 months ago
Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of autoimmune disease - no evidence of overall increase in conditions. Environmental and socioeconomic factors involved in the presentation of the conditions https://t.co/3jy9NoltkG
Dr. Antoni Chan @synovialjoints ( View Tweet )
2 years 3 months ago
×